Abstracts Archive - Page 126 of 2607 - ACR Meeting Abstracts

Abstract Number: 1694 • ACR Convergence 2025
Obesity Exacerbates Autoimmunity by Dysregulating B Cell Behavior
Munir Akkaya, Sohret Gokcek, Billur Akkaya and Wael Jarjour, The Ohio State University, Columbus, OH
Background/Purpose: Obesity is a major public health concern in the United States, affecting over 100 million individuals. While its detrimental effects on multiple organ systems…
Abstract Number: 1775 • ACR Convergence 2025
Study Of Type -1 Interferon Gene Signature Markers In Muscle Biopsy Samples Of Patients With IIM
pradeep sosigowda¹, Phani Kumar D¹, Megha Uppin¹ and Liza rajasekhar², ¹NIMS, Hyderabad, Telangana, India, ²Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune diseases primarily affecting skeletal muscle, with potential involvement of other organs. They are classified…
Abstract Number: 1755 • ACR Convergence 2025
Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
Zoya Qaiyum¹, Michael Tang², Shirin Soleimani³, Addison Pacheco², Melissa Lim⁴, Fataneh Tavasolian⁴, Trevor Pugh³ and Robert Inman², ¹Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1650 • ACR Convergence 2025
Malondialdehyde-Acetaldehyde and Citrulline Modified Proteins are Overexpressed in Cardiac Tissues in Rheumatoid Arthritis-Associated Heart Failure and Mediate Endothelial Cell Dysfunction
Hannah Johnson¹, Wenxian Zhou², Michael Duryee¹, Engle Sharp¹, Kimberley Sinanan¹, Carlos Hunter¹, Tate Johnson¹, Mabruka Alfaidi¹, Daniel Anderson³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ^30587964, Durham, NC
Background/Purpose: Previous reports show that malondialdehyde-acetaldehyde (MAA) adducts are overexpressed in RA, especially in joint/lung tissues, and that they colocalize with citrulline (CIT). This is…
Abstract Number: 1670 • ACR Convergence 2025
Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
Shima Yasin¹, Shima Yasin² and Polly Ferguson³, ¹King Abdullah Specialized Children’s Hospital,Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia, ²Univeristy of Iowa, Iowa City, ³University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease that affects children and adolescents. The disease typically presents with bone pain with or…
Abstract Number: 1764 • ACR Convergence 2025
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Naomi Patel¹, Aaron Wu², Eli Miloslavsky³, Peter Merkel⁴, John Stone⁵, Hyon K. Choi⁶, Zachary Wallace³ and Emily Hyle², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Evaluating the effectiveness and safety profile of treatment strategies for the induction of remission of individuals with newly diagnosed AAV is important for guiding…
Abstract Number: 1744 • ACR Convergence 2025
Preceding Mental Health Diagnosis Does Predict Eventual Neuropsychiatric Disease in Childhood-Onset Systemic Lupus Erythematosus
Ekemini Ogbu¹, Clare Treutel¹, Angela Merritt², Michael Wagner¹ and Hermine Brunner¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Childrens Hospital Medical Center, Cincinnati, OH
Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) affects approximately 1 in 10,000 children in the United States, with the estimated prevalence of childhood neuropsychiatric SLE (NPSLE)…
Abstract Number: 1774 • ACR Convergence 2025
Citrullinated and Malondialdehyde-Acetaldehyde Co-Modified Fibrinogen Activates Macrophages and Induces Pro-Fibrotic shift in Coronary Endothelium Phenotype
Nozima Aripova¹, Wenxian Zhou², Hannah Johnson¹, Michael Duryee¹, Kimberley Sinanan¹, Carlos Hunter¹, Tate Johnson¹, Mabruka Alfaidi¹, Daniel Anderson³, Kishore Bidasee¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ^30587964, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk for developing heart failure with preserved ejection fraction (HFpEF), which is characterized by impaired left ventricular…
Abstract Number: 1520 • ACR Convergence 2025
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Bahtiyar Toz¹, Himanshu Vashistha² and Richard Furie³, ¹Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
Abstract Number: 1657 • ACR Convergence 2025
Extracting TNF Inhibitor Switching Reasons and Trajectories From Real-World Data Using Large Language Models
Brenda Miao¹, Marie Binvignat², Augusto Garcia-Agundez³, Maxim Bravo⁴, Christopher Williams⁵, Claire Miao⁴, Ahmed Alaa⁶, Vivek Rudrapatna⁵, gabriela Schmajuk⁷ and Jinoos Yazdany³, ¹UCSF, Fremont, CA, ²Sorbonne University, Paris, France, ³UCSF, San Francisco, CA, ⁴UC Berkeley, San Francisco, ⁵UCSF, San Francisco, ⁶UC Berkeley, Berkeley, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are cornerstones of autoimmune‑disease therapy, yet many patients switch agents because of loss of effectiveness, adverse events, or insurance…
Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1780 • ACR Convergence 2025
Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
Abdelhak Belmadani¹, Dongjun Ren¹, Daniel Hoffman², Nirupa Jayraj¹, Paola Pacifico¹, Vince Truong³, Patrick Walsh³, Daniela Menichella¹, Anna Rapp⁴, Carla Scanzello⁵, Rachel Miller⁶, Richard Miller⁷ and Anne-Marie Malfait⁸, ¹Northwestern University Chicago, Chicago, IL, ²Rush University, Chicago, IL, ³Anatomic Inc, Minneapolis, MN, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, ⁶Rush University Medical Center, Chicago, IL, ⁷Northwestern University, Chicago, ⁸Rush University Medical Center, Chicago
Background/Purpose: Joint pain is one of the most significant clinical hallmarks of knee osteoarthritis (OA). Knee OA is a chronic degenerative disease of the joints…
Abstract Number: 1530 • ACR Convergence 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Guillermo Pons-Estel¹, Rosana Quintana¹, Romina Nieto¹, Hermine Brunner², Marina Scolnik³, Carmen Funes Soaje⁴, Paula Alba⁵, Veronica Saurit⁶, Mercedes Garcia⁷, GUILLERMO ARIEL BERBOTTO⁸, Inés Verónica Bellomio⁹, Mario Eduardo Kerzberg¹⁰, Graciela Gomez¹¹, Cecilia Pisoni¹², Vicente Juarez¹³, Ana Malvar¹⁴, Nélzio Silva¹⁵, ODIRLEI MONTICIELO¹⁶, Henrique Mariz¹⁷, Francinne Ribeiro¹⁸, Eduardo Borba¹⁹, Eloisa Bonfa¹⁹, Edgard Torres dos Reis-Neto²⁰, Iris Guerra Herrera²¹, Maria Loreto Massardo²², Gustavo Aroca-Martínez²³, Lorena Gómez Escorcia²⁴, Carlos Alberto Cañas²⁵, Gerardo Quintana-Lopez²⁶, Carlos Toro-Gutierrez²⁷, Mario Moreno Alvarez²⁸, MIGUEL SAAVEDRA²⁹, Margarita Portela Hernández³⁰, Hilda Fragoso-Loyo³¹, Luis H Silveira³², Ignacio García-De la Torre³³, Carlos Abud-Mendoza³⁴, Jorge Antonio Esquivel Valerio³⁵, Maria Isabel Acosta³⁶, Astrid Paats³⁷, Claudia S. Mora-Trujillo³⁸, Manuel Ugarte-Gil³⁹, Armando Calvo⁴⁰, Roberto Muñoz-Louis⁴¹, Martin Rebella⁴², Alvaro Danza⁴³, Federico Zazzetti⁴⁴, Ashley Orillion⁴⁵, Urbano Sbarigia⁴⁶ and Bernardo A. Pons-Estel⁴⁷, ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas, GO-CREAR, Rosario, Argentina, Rosario, Argentina, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁵Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁶Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Interzonal General de Agudos “General San Martín” de la plata, La Plata, Argentina, ⁸Sanatorio Británico, Rosario, Argentina, ROSARIO, Argentina, ⁹Hospital Padilla, Tucumán, Argentina, San Miguel de Tucumán, Argentina, ¹⁰Hospital J.M Ramos Mejía, Buenos Aires, Argentina, CABA, Argentina, ¹¹Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno”, Buenos Aires, Argentina, Ciudad Autonoma Buenos Aires, Argentina, ¹³Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁴Organización Médica de Investigación, Buenos Aires, Argentina, ¹⁵Hospital das Clinicas da Universidade Federal de Goias, Goias, Brazil, Goiânia, Brazil, ¹⁶Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁷Universidad Federal de Pernambuco, Pernambuco, Brazil, Pernambuco, Brazil, ¹⁸Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²⁰Universidad Federal São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²¹Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²²Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²³Clínica de la Costa y Universidad Simón Bolívar, Barranquilla, Colombia, barranquilla, Colombia, ²⁴Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁶Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁷Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ²⁸Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ²⁹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, MEXICO, Mexico, ³⁰Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³²Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Jalisco, Mexico, ³⁴Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, San Luis Potosí, Mexico, ³⁵Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁶Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁷Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ³⁸Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ³⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴⁰Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴¹Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴²Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴³Médica Uruguaya, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁴Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁵Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁶Johnson & Johnson, Beerse, Belgium, ⁴⁷Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina
Background/Purpose: Effective, non-invasive disease activity and treatment response assessments are needed for patients with systemic lupus erythematosus (SLE), especially if associated with kidney disease, i.e.…
Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Alexia Zagouras¹, Sammy Pickell¹, Yuhan Liu¹, Ronald Witteles¹ and Matthew Charles Baker², ¹Stanford University, Stanford, CA, ²Stanford University, Menlo Park, CA
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].